Axon Enterprise shares fell roughly 10% Tuesday after the public-safety technology company launched a $1 billion convertible debt offering, adding fresh financing capacity while raising questions about future dilution and how aggressively management plans to deploy capital.
The company is offering $1 billion of 0% convertible senior notes due in September 2031 and is giving underwriters an option to purchase another $150 million. Final conversion terms have not yet been set.
Axon said it plans to use part of the proceeds for capped-call transactions designed to limit potential dilution if the notes are eventually converted into shares. Remaining proceeds can be used for general corporate purposes, including acquisitions, investments and funding further growth.
Shares traded as low as about $435 during Tuesday’s session after closing Monday at $490.18, a drop of more than 11% at the low. The broader market was also weaker as the 10-year Treasury yield approached 5%, but Axon significantly underperformed the major indexes, pointing to the financing announcement as the main company-specific pressure on the stock.
The reaction does not reflect a sudden deterioration in Axon’s operating business.
Revenue increased 35% year over year to $904 million in the second quarter, annual recurring revenue climbed 39% to $1.64 billion and future contracted bookings reached $15.1 billion. Axon raised its full-year revenue-growth forecast last month to between 32% and 34% while maintaining an adjusted EBITDA margin outlook of approximately 25.5%.
Instead, investors are being asked to evaluate what Axon intends to do with substantially greater financial capacity.
Zero Interest Comes With an Equity Trade-Off
The new notes carry no regular interest and their principal will not accrete, making them considerably cheaper from a cash-interest perspective than Axon’s existing conventional debt.
Axon already has $1 billion of 6.125% senior notes due in 2030 and $750 million of 6.25% notes due in 2033. Those securities produced roughly $27 million of contractual interest expense during the second quarter alone.
If the full $1 billion convertible offering is completed, Axon’s principal amount of outstanding notes would rise to about $2.75 billion before any additional over-allotment.
That number alone overstates the immediate balance-sheet impact because Axon will also receive the offering proceeds. The transaction initially adds cash and debt at the same time rather than simply increasing net leverage by $1 billion. How the company eventually spends that cash will determine the longer-term effect.
At June 30, Axon held $685 million in cash, cash equivalents and short-term investments against $1.75 billion of senior-note principal, leaving the company with approximately $1.1 billion of net debt.
The convertible structure gives Axon access to capital without another large fixed-interest obligation, but investors potentially pay for that advantage through future equity dilution.
How much dilution could occur is not yet known because the initial conversion price will be established when the offering is priced.
Axon is attempting to reduce that risk by buying capped-call contracts covering the number of shares initially underlying the notes. Those contracts are intended to offset potential dilution or cash payments above the notes’ principal value up to a predetermined cap price. That cap also has not been announced yet.
Until those terms are priced, shareholders cannot fully calculate the potential equity impact.
Axon Is Also Expanding Its Borrowing Capacity
The convertible offering is part of a broader financing move.
Axon simultaneously amended its revolving credit agreement, increasing the facility from $300 million to $500 million and adding the ability to expand it by another $150 million. The amended revolver is expected to mature as late as September 2031, although the exact maturity can change depending on the status of the new convertible notes and other debt.
Borrowings under the facility would carry interest of SOFR plus 1.25% to 1.75%. Axon had no borrowings outstanding on its existing revolver at the end of June.
Taken together, the convertible notes and larger credit line give management considerably more flexibility for acquisitions and product investment.
That appears consistent with how Axon has been expanding.
The company has pushed beyond TASER devices and body cameras into drones, counter-drone systems, real-time operations, records management, 911 software and AI. Dedrone revenue has already surpassed a $100 million annualized level, while Axon said revenue from products associated with its AI Era strategy increased nearly sevenfold in the second quarter.
The question for shareholders is no longer whether Axon can find areas in which to invest. It is whether the returns from those investments will justify a larger and more complicated capital structure.
Growth Is Strong, but Cash Generation Has Lagged
Axon’s rapid growth makes the financing easier to support, but its recent cash generation provides another reason to watch the balance sheet.
Adjusted EBITDA reached $242 million in the second quarter, up more than 40%, yet operating cash flow was only $20 million and free cash flow was slightly negative. Axon attributed the gap partly to inventory investment needed to support demand and the timing of customer billing and collections.
That is not necessarily a warning sign for a company expanding more than 30% annually, but it means Axon cannot fund every growth initiative simply from current free cash flow.
The company also expects capital expenditures of $160 million to $190 million this year, excluding spending associated with its new headquarters.
Tuesday’s financing therefore gives Axon more room to invest without immediately relying on another conventional high-coupon debt issuance. The 0% rate is attractive. The unresolved issue is what shareholders receive in exchange for accepting the possibility of future dilution.
The next catalyst is the pricing of the notes. Axon still needs to disclose the conversion rate, conversion price and capped-call ceiling. Those figures will show investors how far the stock must rise before meaningful conversion risk emerges and how much protection the company has purchased against dilution.
Until those terms are known, Tuesday’s selloff is less a verdict on Axon’s underlying growth than a repricing of the cost of financing that growth.